Clinical trials: Allergy; Dermatitis
Stevens-Johnson Syndrome, Corneal Blindness
Infliximab to Improve Retention of the Boston Keratoprosthesis in Patients After Stevens Johnson Syndrome/ Toxic Epidermal Necrolysis (SJS/TENS)
The proposed study is intended to test the idea, based upon current knowledge of the biology and physiology of corneal ulceration in SJS/TENS patients who receive a keratoprosthesis, and on the known effects of infliximab on…
- Trial name
- NCT01256489
- Testing
- Infliximab
- Where
- United States
- Sponsor
- Massachusetts Eye and Ear Infirmary
Atopic Dermatitis
Effects of a Mixed Chinese Herbal Formula on Atopic Dermatitis
The aim of this study is to investigate the clinical therapeutic effects of a mixed Chinese herbal formula (CHF) in treating atopic dermatitis (AD) based on its effects on cytokine levels and immune cell counts.
- Trial name
- NCT05455060
- Testing
- Chinese herbal formula (CHF)
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Chang Gung Memorial Hospital
Atopic Dermatitis
Efficacy and Safety of Orally Administered DS107 in Adult Patients With Moderate to Severe Atopic Dermatitis
The objective of this study is to compare the efficacy and safety of orally administered DS107 (2g) versus placebo in the treatment of moderate to severe Atopic Dermatitis (AD).
- Trial name
- NCT03817190
- Testing
- DS107
- Where
- 50 sites in United States, Austria and 3 more
- Volunteers
- 219 people
- Sponsor
- DS Biopharma
Mild to Moderate Atopic Dermatitis
Evaluation of the Effect of the Product RV4660C CY0203 on Clinical, Biometrological and Biological Parameters in Adults With Mild to Moderate Atopic Dermatitis, an Exploratory Study
In this exploratory study, we assessed the efficacy of a cosmetic product in adults suffering from mild to moderate atopic dermatitis. This exploratory study has been conducted as a monocentric non randomized study.
- Trial name
- NCT07166497
- Testing
- Cosmetic product RV4660C CY0203
- Where
- France
- Volunteers
- 21 people
- Sponsor
- Pierre Fabre Dermo Cosmetique
Dermatitis, Atopic, Eczema
Behavioral Self-Help Intervention for Pediatric Atopic Dermatitis and Eczema Patients
Patients with atopic dermatitis and eczema often struggle with habitual scratching that is not well-controlled even with optimal medical therapy.
- Trial name
- NCT02713035
- Testing
- Self help intervention
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Mississippi Medical Center
Atopic Dermatitis
Immune Response to Yellow Fever Vaccination in Adults With Atopic Dermatitis
The main objective of the Atopic Dermatitis and Vaccinia Immunization Network (ADVN) is to reduce the risk of the fatal reaction, eczema vaccinatum (EV), to the smallpox vaccination in those with atopic dermatitis (AD).
- Trial name
- NCT00723489
- Testing
- Live Yellow Fever Vaccine (YFV-17D)
- Where
- 3 sites in United States
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Atopic Dermatitis
Impact of the Daily Use of Emollient on Corticosteroids Consumption in Patients With Atopic Dermatitis
This study aims at assessing the reduction of consumption of corticosteroids (same mid-potent corticosteroids for all patients) afforded by the use of a specific emollient in comparison to the usual one in subjects suffering from…
- Trial name
- NCT05644691
- Testing
- Lipikar Baume AP+M, Usual emollient
- Where
- Slovakia
- Volunteers
- 119 people, healthy volunteers welcome
- Sponsor
- Cosmetique Active International
Cutaneous T-cell Lymphoma, Sezary Syndrome
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
This is a tissue, urine, and blood banking protocol for cutaneous t-cell lymphoma (CTCL), eczema, and atopic dermatitis patients for current and future research.
- Conditions
- Cutaneous T-cell Lymphoma, Sezary Syndrome, Mycosis Fungoides, Eczema
- Trial name
- NCT00177268
- Testing
- Blood draw, skin biopsy or urine collection
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- University of Pittsburgh
Diarrhea, Atopic Dermatitis
Cesarean Section Study
Effect, tolerance and safety of a supplementation with a probiotic on the risk of gastrointestinal infections, on growth, and on gut microbiota in healthy newborn term infants born by Cesarean section.
- Trial name
- NCT01992497
- Testing
- Probiotic
- Where
- Germany
- Volunteers
- 721 people, healthy volunteers welcome
- Sponsor
- Société des Produits Nestlé (SPN)
Atopic Dermatitis
A Study to Assess Bioavailability of Rocatinlimab (AMG 451) Vial and Prefilled Syringe in Healthy Participants
The primary objective of the study is to evaluate the pharmacokinetics (PK) of rocatinlimab given as a single subcutaneous (SC) dose in a vial compared to a prefilled syringe in healthy participants.
- Trial name
- NCT06268860
- Testing
- Rocatinlimab vial injection, Rocatinlimab prefilled syringe
- Where
- 4 sites in United States, United Kingdom
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Amgen
Allergic Asthma, Allergic Rhinitis
Study of the Frequency and of the Regulatory Function of Positive T Lymphocytes Dual CD4CD8aa (DP8a) Specific to a Bacteria of the Intestinal Microbiota (Faecalibacterium Prausnitzii) in Atopic Dermatitis, Asthma and Allergic Rhinitis
The prevalence of allergic diseases (atopic dermatitis, asthma, rhinitis, conjunctivitis and food allergy) has increased dramatically in industrialized countries over the last 20-30 years.
- Conditions
- Allergic Asthma, Allergic Rhinitis, Atopic Dermatitis
- Trial name
- Prévall-DP (NCT02908360)
- Testing
- double positive T cells (CD4 + / CD8 +) to the specific peripheral blood of F prauznitzii analyse
- Where
- France
- Volunteers
- 56 people
- Sponsor
- Nantes University Hospital
Dermatitis Atopic
A Study to Investigate Vaccine Responses in Subcutaneous Amlitelimab Treated Atopic Dermatitis Participants Aged 18 Years and Older Compared With Placebo
This is a Phase 2, multicenter, randomized, double-blind placebo controlled, 2-arm study to evaluate the effect of amlitelimab on vaccine antibody responses, and the safety of amlitelimab concurrently administered with non-live…
- Trial name
- HYDRO (NCT06015308)
- Testing
- Amlitelimab, Tdap vaccine, PPS vaccine
- Where
- 57 sites in United States, Canada
- Volunteers
- 224 people
- Sponsor
- Sanofi
Psoriasis, Atopic Dermatitis
Cross-Sectional Study for an Ocular Imaging-Based Predictive Model of Inflammatory Skin Diseases Grounded in Traditional Chinese Medicine
This study is a cross-sectional, observational investigation designed to develop and validate a noninvasive ocular imaging-based predictive model for major inflammatory skin diseases, including psoriasis, atopic dermatitis, and…
- Trial name
- NCT07434076
- Testing
- Questionnaire collection
- Volunteers
- 950 people, healthy volunteers welcome
- Sponsor
- Shanghai Yueyang Integrated Medicine Hospital
Atopic Dermatitis (Eczema)
Assessment of cfDNA-STING Axis as a Potential Pathological Marker in Atopic Dermatitis
Study Overview Atopic dermatitis (AD), commonly known as eczema, is a chronic inflammatory skin condition characterized by intense itching and skin barrier damage.
- Trial name
- NCT07573735
- Testing
- blood sampling
- Where
- China
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Zhongda Hospital
Atopic Dermatitis
Assessment of the Effects on Barrier Impairment, Clinical Features and Bacterial Colonization of Topical Formulations in Patients With Atopic Eczema; a Phase IIa, Single-center, Randomized, Observer-blind Study
The purpose of the study is the assessment of the barrier impairment, clinical skin condition and bacterial colonization status in patients with atopic eczema following topical treatment with K201 cream and a comparator twice…
- Trial name
- NCT00863005
- Testing
- K201
- Where
- Germany
- Sponsor
- Moberg Pharma AB
Atopic Dermatitis (Eczema)
Safety Study of Roflumilast Cream 0.05% in Infants Aged 3 Months to Less Than 2 Years With Atopic Dermatitis
This study will assess the safety and tolerability of ARQ-151 cream 0.05% applied once a day for 4 weeks in infants with atopic dermatitis (eczema).
- Trial name
- NCT06998056
- Testing
- ARQ-151 cream 0.05%
- Where
- 22 sites in United States, Canada and 1 more
- Volunteers
- 101 people
- Sponsor
- Arcutis Biotherapeutics, Inc.
Atopic Dermatitis (AD)
The Impact of Botox on Neuroimmune Interactions in Atopic Dermatitis
The purpose of this study is to understand cellular and molecular interactions in the skin of participants with mild-to-moderate AD, and how botulinum toxin alters these interactions.
- Trial name
- AD (NCT06928246)
- Testing
- Onabotulinum Toxin Type A - Phase 1b, Onabotulinum Toxin Type A - Phase 2
- Where
- 2 sites in United States
- Volunteers
- 8 people
- Sponsor
- Daniel Kaplan
Atopic Dermatitis, Eczema
A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis
The main purpose of this study is to assess the long-term safety and efficacy of lebrikizumab in participants 6 Months to <18 years of age with moderate-to-severe atopic dermatitis.
- Trial name
- ADorable-2 (NCT05735483)
- Testing
- Lebrikizumab
- Where
- 94 sites in United States, Argentina and 11 more
- Volunteers
- 338 people
- Sponsor
- Eli Lilly and Company
Foramen Ovale, Patent, Nickel Sensitivity
Investigation of Nickel Sensitization After Percutaneous Implantation of Patent Foramen Ovale Occluder
Percutaneous PFO closure has been established as a first-line therapy for preventing recurrent strokes in selected patients. The devices used for the specific purpose contain and release nickel, which is considered as the most…
- Conditions
- Foramen Ovale, Patent, Nickel Sensitivity, Dermatitis Contact Irritant, Metal Allergy
- Trial name
- INSPIRE (NCT04713683)
- Testing
- Percutaneous Patent Foramen Ovale Closure
- Where
- Greece
- Volunteers
- 96 people
- Sponsor
- National and Kapodistrian University of Athens
Atopic Dermatitis
CLINICAL EFFICACY OF EMOLLIENTS IN ATOPIC DERMATITIS PATIENTS
his was a monocentric, intra-individual study, that was performed in at least 45 valid cases (50% children ≥3 YO; 50% adults). Study duration was 168 days with five (5) visits (D0, D14, D28, D84 and D168) to the research center.
- Trial name
- NCT05783453
- Testing
- Cosmetic study
- Where
- Brazil
- Volunteers
- 63 people
- Sponsor
- Cosmetique Active International
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.